Share
Share today's newsletter with a colleague and get credit if they sign up for SmartBrief.
Referral Count:
 
0

Story being shared
EpiCept, Immune Pharmaceuticals sign merger deal
Swedish drugmaker EpiCept entered into a merger agreement with Immune Pharmaceuticals. The combined firm will retain the name Immune Pharmaceuticals and will specialize in antibody drugs and targeted therapies for inflammatory diseases and cancer.

Or we can send an email on your behalf
You must submit valid email addresses only. Use of email addresses is subject to terms of SmartBrief's privacy policy .